Table 1 Correlation between HER2 IHC expression status and clinicopathological parameters

Total

n = 857

n = 13 (1.5%)

n = 52 (6.1%)

n = 792 (92.4%)

Age at diagnosis

0.835

  ≥ 60 years

512

8 (1.6)

29 (5.7)

475 (92.8)

  < 60 years

345

5 (1.4)

23 (6.7)

317 (91.9)

Gender

0.028

Male

712

11 (1.5)

36 (5.1)

665 (93.4)

Female

145

2 (1.4)

16 (11.0)

127 (87.6)

Tumor differentiation

0.203^a

Well

105

0 (0.0)

2 (1.9)

103 (98.1)

Moderate

469

6 (1.3)

31 (6.6)

432 (92.1)

Poor

241

6 (2.5)

16 (6.6)

219 (90.9)

Basaloid

36

1 (2.8)

2 (5.6)

33 (91.7)

Spindle cell

3

0 (0.0)

1 (33.3)

2 (66.7)

Basaloid + spindle cell

3

0 (0.0)

0 (0.0)

3 (100)

pT status

0.584

pT1

190

5 (2.6)

15 (7.9)

170 (89.5)

pT2

145

2 (1.4)

6 (4.1)

137 (94.5)

pT3

468

6 (1.3)

27 (5.8)

435 (92.9)

pT4

54

0 (0.0)

4 (7.4)

50 (92.6)

pN status

0.221

pN0

434

5 (1.2)

27 (6.2)

402 (92.6)

pN1

235

6 (2.6)

11 (4.7)

218 (92.8)

pN2

149

2 (1.3)

8 (5.4)

139 (93.3)

pN3

39

0 (0.0)

6 (15.4)

33 (84.6)

pM status

NA

pM0

856

13 (1.5)

52 (6.1)

791 (92.4)

pM1

1

0 (0.0)

0 (0.0)

1 (100)

pTNM stage

0.134

I

166

2 (1.2)

13 (7.8)

151 (91.0)

II

274

5 (1.8)

16 (5.8)

253 (92.3)

III

360

6 (1.7)

15 (4.2)

339 (94.2)

IV

57

0 (0.0)

8 (14.0)

49 (86.0)